by AbbVie
Wed, 06/14/2017
AbbVie, a global biopharmaceutical company, and Principia Biopharma Inc., a private, clinical-stage biopharmaceutical company, announced that they have entered a collaboration for the development of oral immunoproteasome inhibitors. The collaboration is aimed at developing first-in-class oral therapies that bring the power of proteasome inhibition safely into the field of immunology.
"Principia has discovered a novel technology that has the potential to enhance the treatment landscape for a variety of immunological diseases," said Lisa Olson, vice president, immunology research, AbbVie. "The combination of AbbVie's world-class expertise in immunology drug development with Principia's innovative approach to immunoproteasome inhibitors may offer patients a new class of therapies to treat serious and chronic conditions."
"As a world leader in immunology and inflammation, AbbVie is an ideal fit for Principia's reversible covalent inhibitors, also known as Tailored Covalency™," said Martin Babler, chief executive officer, Principia. "This collaboration brings together the best of both companies, accelerating our program toward the clinic."
The collaboration contemplates the creation and development of orally bioavailable, selective inhibitors of the immunoproteasome subunits to target autoimmunity. AbbVie and Principia will collaborate on research and pre-clinical studies. Upon successful completion, AbbVie will be responsible for ongoing clinical development and commercialization of viable compounds resulting from the partnership. Financial terms were not disclosed.
Read online article
